CAROLINA BUITRAGO: Open Payments
NPI 1528592532 · MIAMI, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,551 in 35 payments from 14 companies in 2025. Trend: 2023 $437 · 2024 $1,351 · 2025 $1,551
Food & beverage: $1,551
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 4 | $489 |
| Amgen Inc. | 6 | $207 |
| AstraZeneca Pharmaceuticals LP | 5 | $202 |
| Edwards Lifesciences Corporation | 2 | $144 |
| Lilly USA, LLC | 1 | $125 |
| Boston Scientific Corporation | 3 | $85 |
| E.R. Squibb & Sons, L.L.C. | 4 | $79 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $60 |
| Merck Sharp & Dohme LLC | 2 | $42 |
| BIOTRONIK INC. | 1 | $26 |
Products named: Wegovy, REPATHA, LOKELMA, Ozempic, ZEPBOUND, WATCHMAN FLX, FARXIGA, ELIQUIS.
Industry payments across FL — which companies pay providers there.
